Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
2.255
-0.025 (-1.10%)
Streaming Delayed Price
Updated: 12:28 PM EST, Mar 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
April 21, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
↗
April 10, 2025
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Via
Benzinga
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
↗
April 10, 2025
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.
Via
Stocktwits
Topics
World Trade
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
April 09, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Monday's session: gap up and gap down stocks
↗
April 07, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Tempest Reports Year End 2024 Financial Results and Provides Business Update
March 27, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment
From
Tempest Therapeutics
Via
GlobeNewswire
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
March 13, 2025
Second clinical program entering Phase 2 with data expected 2026
From
Tempest Therapeutics
Via
GlobeNewswire
Tuesday's after hours session: top gainers and losers
↗
March 04, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 10, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 06, 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
November 12, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 30, 2024
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
↗
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
October 10, 2024
Via
Benzinga
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
↗
October 10, 2024
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 10, 2024
Via
Benzinga
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
October 10, 2024
The company is preparing for the Phase 3 study start in the first quarter of 2025
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Extends Limited Duration Stockholder Rights Plan
October 10, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
September 18, 2024
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 21, 2024
Expansion of leadership team to strengthen global clinical expertise
From
Tempest Therapeutics
Via
GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
↗
August 15, 2024
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
